Article Text

Download PDFPDF
Highlights from the literature: inflammatory bowel disease
  1. Rafeeq Muhammed
  1. Department of Paediatric Gastroenterology, Birmingham Children’s Hospital, Birmingham B4 6NH, UK
  1. Correspondence to Dr Rafeeq Muhammed, Paediatric Gastroenterology, Birmingham Children’s Hospital, Birmingham B4 6NH, UK; rafeeq.muhammed{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

CALM trial showed tight control resulted in better outcomes for patients with Crohn’s disease 

CALM trial compared endoscopic and clinical outcomes in patients with moderate to severe Crohn’s disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm.1 This was an open-label, randomised, controlled phase 3 study, done in 22 countries which evaluated adult patients with active endoscopic Crohn’s disease, and no previous use of immunomodulators or biologics. Patients were randomly assigned at a 1:1 ratio to tight control or clinical management groups, stratified by smoking, weight and disease duration after 8 weeks of prednisone induction therapy, or earlier if they had active disease. Treatment was escalated in both groups in a stepwise manner, from no treatment, to adalimumab induction followed by adalimumab every other week, adalimumab every week and, lastly, to both weekly adalimumab and daily azathioprine. In the tight control group the therapy escalation was initiated if a patient’s Crohn’s Disease Activity Index (CDAI) score was at …

View Full Text


  • Contributors RM is the sole contributor to this paper.

  • Competing interests RM has received speaker fees, travel support and research grants, or has performed consultancy work with MSD Immunology, AbbVie, Dr Falk Pharma, 4D Pharma, Tillotts Pharma, Nestle, Takeda, Ferring and Pfizer.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.